Tier 2 — strong
Significant pharmacokinetic differences of berberine are attributable to variations in gut microbiota between Africans and Chinese
Scientific reports
2016
6:27671
Bibliography
- PubMed
- PMID 27283523
- PubMed Central
- PMC4901288
- Funding
- Funding was not established from the accessible source; this is not a declaration of no funding.
- Competing interests
- A complete competing-interest declaration was not available in the accessible source; no absence of conflicts is inferred.
Study snapshot
| Design | Comparative pharmacokinetic and microbiome study |
|---|---|
| Model | Human participants; see population |
| Sample | 20 healthy men; 10 African and 10 Chinese participants |
| Intervention | Single oral berberine hydrochloride 600 mg (542.8 mg active berberine), with breakfast; gut-microbiota profiling |
| Duration | 12-hour pharmacokinetic sampling |
| Endpoints | Plasma exposure and pharmacokinetics; Drug interaction measurements; Short-term tolerability |
What the study showed, in plain terms
Key findings
What this study can and cannot tell us
Citation network
Articles citing this research paper
Biohack Blueprint analyses that reference this study in their evidence base.
Editorial review
Reviewed by the Biohack Blueprint research team
Last verified
